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Abstract
Previous GWAS studies have reported significant associations between various common SNPs
and prostate cancer risk using cases unselected for family history. How these variants influence
risk in familial prostate cancer is not well studied. Here, we analyzed 25 previously reported SNPs
across 14 loci from prior prostate cancer GWAS. The International Consortium for Prostate
Cancer Genetics (ICPCG) previously validated some of these using a family-based association
method (FBAT). However, this approach suffered reduced power due to the conditional statistics
implemented in FBAT. Here, we use a case-control design with an empirical analysis strategy to
analyze the ICPCG resource for association between these 25 SNPs and familial prostate cancer
risk. Fourteen sites contributed 12,506 samples (9,560 prostate cancer cases, 3,368 with aggressive
disease, and 2,946 controls from 2,283 pedigrees). We performed association analysis with Genie
software which accounts for relationships. We analyzed all familial prostate cancer cases and the
subset of aggressive cases. For the familial prostate cancer phenotype, 20 of the 25 SNPs were at
least nominally associated with prostate cancer and 16 remained significant after multiple testing
correction (p≤1E−3) occurring on chromosomal bands 6q25, 7p15, 8q24, 10q11, 11q13, 17q12,
17q24, and Xp11. For aggressive disease, 16 of the SNPs had at least nominal evidence and 8
were statistically significant including 2p15. The results indicate that the majority of common,
low-risk alleles identified in GWAS studies for all prostate cancer also contribute risk for familial
prostate cancer, and that some may be contribute risk to aggressive disease.
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Introduction
Previous prostate cancer GWAS have reported associations between various SNPs and
prostate cancer in cohorts of prostate cancer cases unselected for family history
(Amundadottir 2006; Duggan 2007; Gudmundsson 2007a; Gudmundsson 2007b; Haiman
2007; Eeles 2008; Gudmundsson 2008; Salinas 2008; Sun 2008; Thomas 2008). The
International Consortium for Prostate Cancer Genetics (ICPCG) selected 25 of these SNPs
to pursue replication of these findings in a set of related hereditary prostate cancer cases
selected for membership in high-risk pedigrees. A previous analysis of the ICPCG data used
family based association testing (FBAT) on 102 – 477 informative families and was able to
confirm three of these candidate SNPs (p≤2E−3 (= 0.05/25)) (Jin 2012). Here a larger
analysis of the same 25 SNPs in over 12,000 individuals was conducted using a case-control
framework that allowed analysis of all data submitted by ICPCG member sites without
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restriction to the trio relationship structure. The increased sample size considerably
improves statistical power to study these SNPs.
Fourteen study sites contributed a total of 12,506 samples for genotyping, including 2,946
controls, 6,192 cases with non-aggressive disease, and 3,368 cases with aggressive disease.
Genotyped samples originated from 2,283 pedigrees. Each site contributed its own controls,
with an average of 231 controls per site, except for one site that provided genotype data for
931 genetically matched publicly available controls. It is well known that close relationships
can have an inflationary effect on statistics for tests of association, therefore, it was
necessary to account for known relationships in the analysis. Genie software was used to
accomplish this (Allen-Brady 2005; Curtin 2007). Genie generates an empirical null
distribution, matched for the known pedigree structures and multiple sites, from which to
assess the observed test statistic for significance. In this study 10 million such simulations
were used to estimate the necessary null distributions. Separate analyses for all familial
prostate cancers and the subset of aggressive prostate cancers were conducted.
Methods and Materials
Sample cohort
Fourteen member sites of the ICPCG consortium provided samples for analysis; these sites
were the African American Hereditary Prostate Cancer Consortium (AAHPC), the Anglo/
Canadian/Texan/Australian/Norwegian/European Union Biomed (ACTANE), University of
Tampere (Finland), Fred Hutchinson Cancer Research Center (FHCRC), Centre de
Recherche pour les Pathologies Prostatiques (France), Johns Hopkins University (JHU), the
Mayo Clinic (Mayo), The University of Michigan (Michigan), The University of Montreal
(Montreal), Northwestern University (NW), Stanford University (Stanford), University of
Umea (Sweden), University of Ulm (Ulm), and University of Utah (Utah). Each site
recruited study participants according to their own protocols; however, for consistency,
confirmation from either death certificate or medical records was required for a diagnosis of
prostate cancer.
Table 1 provides the number of cases analyzed from each site. Each site also provided
control samples, which were: unaffected pedigree members; regionally selected and
ethnically matched controls; or (for one site) in silico controls. The in silico controls were
supplied by Michigan, who provided 931 controls from the Illumina Genotype Control
Database (iControlDB) (www.illumina.com) that had been genetically matched to their set
of cases using 610K SNPs (Genomic Inflation Factor (Clayton 2005) of 1.018). Several sites
also provided population ascertained cases (non-familial) that were used as another
comparator group in a secondary genetic risk score analysis (n = 1,872).
All cases analyzed in this study from all study sites were of Caucasian ethnic background
with the exception of the cases supplied by the AAHPC site which were all from African
American pedigrees.
Phenotypes
In order to address the potential for clinical heterogeneity across all sites, we imposed
standardized criteria for prostate cancer status. All prostate cancer cases were confirmed by
death or medical record. Each was designated as non-aggressive, aggressive, or
undetermined aggressive status. Cases were considered aggressive if they were categorized
as regional or distant stage, poorly differentiated or non-differentiated grade, or had
evidence for death due to metastatic prostate cancer (Schaid 2006; Christensen 2007). Two
phenotypes were analyzed. The first phenotype consisted of all prostate cancer cases in the
pedigrees regardless of aggressiveness. A separate analysis of aggressive cases only was
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also performed; with comparisons made both to controls and to all non-aggressive prostate
cases.
Genotypes
SNPs were selected for genotyping based on previously published reports that an allele at
the SNP was significantly associated with prostate cancer; SNPs are shown in Table 2.
These SNPs occurred at cytogenetic bands 2p15, 3p12, 6q25, 7p15, 7q21, 8q24, 9q33,
10q11, 10q26, 11q13, 17q12, 17q24, 19q13 and Xp11. Genotyping was performed with
MassARRAY iPLEX (Sequenom, Inc., San Diego, CA) at the Center for Cancer Genomics,
Wake Forest University and is further described elsewhere (Jin 2012). Since imputation of
missing genotypes is not possible given the paucity of genotyped SNPs, individuals with
missing data at particular SNPs were ignored in those analyses.
Statistical Methods
The vast majority of the cases analyzed in this study reside in high-risk pedigrees. It is well
known that standard association techniques are not appropriate for related individuals due to
lack of independence of genotypes. Analyses were conducted with Genie software, which
allows for valid analysis of all data, whether independent or not. To account for relatedness,
Genie software compares the observed test statistic to an empirical null distribution derived
from simulated data sets matched for pedigree structure but generated under the null
hypothesis. In brief, the pedigree founders are assigned alleles based on their population
frequencies and alleles of subsequent pedigree members are assigned according to random
Mendelian inheritance of the founder alleles (a ‘gene-drop’). Test statistics are calculated for
each null simulation to determine a null distribution from which the observed statistic can be
assessed and an empirical p-value is assigned. Singleton cases/controls are simply
considered as founders with no descendants. For multi-site analyses, simulations are
generated in a site-specific manner and overall association evidence is based on a Cochran-
Mantel-Haenzsel meta-statistic across sites (Mantel 1959; Agresti 1990; Curtin 2007). The
primary analysis was the allele test for association for each of the 25 SNPs (asymptotically
equivalent to a trend test). Up to 10 million simulations were used in the null distribution to
estimate p-values, depending on the necessary resolution required. Analysis began with
10,000 simulations and for SNPs with an empirical p-value ≤ 0.1, an additional 10x number
of simulations were performed; this process was repeated until a maximum of 10 million
simulations were performed. A significance threshold of p ≤ 1E−3 was used to declare
statistical significance accounting for multiple tests, which represents a Bonferroni corrected
p-value for 25 tests and 2 phenotypes (corrected alpha = 0.05/50). A Q-test was used to
identify SNPs that exhibited significant heterogeneity across sites.
As follow-up, secondary to the main effects analyses described above, three additional
analyses were performed using Genie. First, we tested all two-way interactions between all
pairs of SNPs (assessed by significance of the interaction coefficient in a logistic regression
framework). Second, we compared aggressive cases to non-aggressive cases by recoding
aggressive cases as ‘cases’ and non-aggressive cases as ‘controls’ and performed tests of
association at each marker. Third, we estimated a genetic risk score based on the number of
risk alleles carried across the SNPs identified as significant in the main analyses. To avoid
sparse data for the number of risk alleles, the extremes of the scale were collapsed to contain
the top/bottom 5% of the data, the resulting categories were: 0–8, 9, 10, …, 16, 17, 18–32
risk alleles carried. Only individuals with genotype data at all markers were included in the
analysis. A trend test across these groups, weighted by the number of risk alleles, was used
to compare the distributions for cases and controls. The genetic risk score test was repeated
using the non-familial cases supplied by several of the contributing sites in order to establish
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the extent to which the genetic risk may differ between familial and non-familial prostate
cancer cases.
Results
Table 3 shows the results of the primary analyses: meta-analysis combining data from all
sites for the phenotypes consisting of all prostate cancer cases and for aggressive cases only.
For the prostate cancer phenotype, 20 of the 25 SNPs were nominally significant (p≤0.05),
and 16 remained statistically significant after correction for multiple testing (p-values
ranging from 1E−3 to ≤1E10−7). Replicated SNPs were on chromosomal bands 6q25, 7p15,
8q24, 10q11, 11q13, 17q12, 17q24, and Xp11. The odds ratios for all but 1 of the significant
SNPs were less extreme than the originally published findings, as is often the situation in
replication studies, although perhaps surprising for familial cases (Table 3).
For the aggressive prostate cancer phenotype, 16 markers showed at least nominal evidence
and 8 of the 25 SNPs were statistically significant after correcting for multiple testing (p-
values ranging from 1.3E−3 to ≤1E10−7). Qualitatively, the results for the aggressive
phenotype were similar to the results of all prostate cancer cases indicating that these SNPs
do not offer substantial discrimination between these two clinically distinguishable
phenotypes. For any SNPs that were significant for both phenotypes, the odds ratio was
consistently more extreme for aggressive prostate cancer; although none were significantly
different. In accordance with this, in the secondary analysis of aggressive versus non-
aggressive disease, no statistically significant differences were found (results not shown).
The results for the 14 study sites are reported in Supplemental Figure 1 for all prostate
cancer and in Supplemental Figure 2 for aggressive prostate cancer, depicted in Forrest
plots. Four SNPs indicated significant heterogeneity across sites (Q-test p ≤1E−3); two at
8q24 (rs1447295; rs10090154), 9q33 (rs1571801), and Xp11 (rs5945619). Three of these 4
SNPs were significantly replicated, and by inspection of the Forrest plots it can be seen that
the by-site odds ratio estimates vary with one or two sites having extreme risk estimates but
in the same direction as the meta-analysis result. The fourth SNP, at rs1571801 on 9q33,
was not significant in the meta-analysis. It is notable that for this SNP the AAHPC site had a
by-site significant OR estimate (OR = 1.7; 95% CI = (1.2, 2.5)) which was in the opposite
direction from most of the other sites. The odds ratio estimate for the aggressive phenotype
for this site at this marker was even more extreme (OR = 2.4; 95% CI = (1.5, 4.4)). The
AAHPC site differs from the other sites in that it is composed of African American families,
indicating that this SNP may have a role in familial prostate cancer for this ethnic group
even though the marker failed to achieve significance overall. The SNP rs1571801 is an
intronic polymorphism in the DAB2IP gene, a documented tumor suppressor that has been
observed to be aberrantly methylated in some prostate and lung cancers (Yano 2005) and
has been associated with early onset prostate cancer in a set of 754 Caucasians (Lange
2012). According to 1000 Genomes project, the minor allele frequency of this SNP does
exhibit some variation between ethnic groups (5% in Asians; 15% in Africans; 20% in ad-
mixed Americans; 24% in Europeans), indicating that this SNP may be in linkage
disequilibrium with some causal variant(s) in the African American prostate cancer families
in this study, but not in the familial cases studied with other ancestral backgrounds.
The analysis of all two-way interactions failed to identify any statistically significant
interactions, after adjusting for multiple testing.
The results of the genetic risk analysis appear in Table 4. The Table shows the ORs and 95%
CIs of familial cases and controls comparing the number of risk alleles carried across the 16
replicated SNPs. In a test for trend weighted by the number of risk alleles, familial prostate
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cancer cases were significantly different than controls (p ≤ 1E−6). The results presented in
Table 4 show that several adjacent categories of risk alleles carried exhibit similar levels of
risk and could be collapsed. For instance, using a baseline of ≤8 risk alleles (lowest 10% of
distribution), the increased risk for familial cases was approximately 1.6 for 9 or 10 risk
alleles (19% of the population), 1.93 for 11–13 risk alleles (40%), and 2.84 for 14+ alleles
(31%). It is notable that when taken together, these 16 risk loci appear to be able to
distinguish extreme groups that could be clinical valuable for determining early or more
frequent screening for prostate cancer prevention. This analysis was repeated for population
cases (results appear in Supplemental Table 1) and also found to be highly significant (p ≤
1E−6). The increased risks were estimated to be approximately 1.40 for 9 or 10 risk alleles,
1.70 for 11–13 risk alleles, and 2.74 for 14+ alleles. The difference between familial and
population cases was statistically significant (p ≤ 1E−6), with familial cases carrying more
risk alleles, further confirming that family history is an important determinant in prostate
risk.
Discussion
This familial case-control analysis of 9,560 familial prostate cancer cases significantly
confirmed 16 of 25 SNPs (p ≤ 1E−3) previously reported to be associated with prostate
cancer in population-based GWAS. This is compared to only three SNPs that could be
replicated at the same significance using a FBAT analysis nested in the same genotype data
(Jin 2012). The clear advantage of this analysis strategy (using related familial cases in a
traditional case-control design) is the ability to use all the available genotype data. This
produced a notable enhancement to statistical power. With the increased sample size, there
was sufficient power for a subset analysis for aggressive disease, for which association of a
SNP in the 2p15 locus for these familial cases was validated. Specifically, beyond the three
loci with significant evidence from the FBAT analysis (10q11, 17q24 and Xp11), significant
replication evidence for SNPs at 5 additional loci was shown: 2q15 (aggressive disease
only), 7p15, 8q24, 11q13, and 17q12.
The results of this analysis highlight the benefit of using the case-control design, even with
family-based data. The approach reported here was enabled by the flexible empirical
approach contained in the Genie software that can appropriately account for the relatedness
among cases. Furthermore, Genie software also provides a valid means to adjust for site-
specific effects in a meta-analysis framework, and the ability to test for interaction effects
and multi-locus analyses (such as a genetic risk score).
An analysis of familial aggressive cases versus familial non-aggressive prostate cancer cases
was performed, but did not identify any statistically significant differences. This outcome
indicates that, at least for the definition of aggressiveness that we used, these 25 SNPs do
not distinguish between risk for aggressive and non-aggressive prostate cancer. The fact that
two regions failed to achieve significance in the aggressive phenotype analysis but did
achieve significance in the all-PRCA phenotype analysis (6q25 and 7p15) indicates that this
outcome is more likely an artifact of diminishing sample size and not due to a clinically
important mechanism between the two disease definitions (the two analyses provided very
similar odds ratios).
The genetic risk score based on the 16 replicated SNPs was an attempt to consider the multi-
locus combined risk across multiple disease-associated SNPs. This analysis revealed that,
although the individual SNP ORs were less extreme than the initial reports, that considering
all 16 loci together, the familial prostate cancer cases carry significantly more risk alleles
than do sporadic cases, indicating that they are enriched for these genetic associations. This
outcome indicates that these families may be of great value for sequencing efforts to identify
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the genetic factors underlying these associations. Indeed, the ICPCG has already made a
strong effort towards that objective. This observation of stronger genetic risk in familial
disease is consistent with a recent report that positive family history doubles lifetime risk of
prostate cancer above that attributable to carrying all risk alleles across 26 common variants
(MacInnis 2011). Another recent report of a genetic risk score analysis comparing
population ascertained cases and controls compared genotypes collected on 33 common
variants previously shown to be associated with prostate cancer and demonstrated only a
marginal improvement in prostate cancer prediction over prostate specific antigen screening
alone (Johansson 2012). This question remains to be answered for familial prostate cancer
where the effects appear to be larger.
In conclusion, these observations support that the majority of SNPs identified from GWAS
using population-based case-control cohorts likely also play a role in the risk of familial
disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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